Safiglipron
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
Shandong Suncadia Medicine Co · Phase 1/2 · Completed · Enrollment 74
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Treatment group A | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group B | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group C | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group D | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group E | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group F | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group G | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group H | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group I | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group J | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group K | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group L | Obesity or overweight | n/r | n/r | n/r | n/r |